Drugs / ZL-3101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03134352 | Apr 2017 → May 2018 | dermatitis | Zai Lab Pty. Ltd. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-08-24 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis zailaboratory.com ↗
Although the study showed that topical ZL-3101 was safe and well-tolerated, the treatment showed no difference compared to placebo in the primary efficacy endpoint, a change in the Eczema Area and Severity Index (EASI) score at day 21. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-24 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis zailaboratory.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-3101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03134352 ↗ |
| Route | Topical | “Topical” NCT03134352 ↗ |